So-called arthroscopic knee surgery is becoming a less common treatment for adults with torn cartilage or painful arthritis as a growing body of evidence shows little benefit from these operations, a U.S. study suggests.
With Phase II Win for Ankylosing Spondylitis, Gilead and Galapagos’ Filgotinib Inches Toward Approval
Gilead Sciences Inc. and its partner Galapagos NV announced results from the Phase II TORTUGA clinical trial of filgotinib, a selective JAK1 inhibitor, in adults with moderately to severely active ankylosing spondylitis.
Watertown, Mass.-based Selecta Biosciences is eying a Phase III trial for its gout treatment based on expanded positive data from an ongoing mid-stage study that showed a significant reduction of serum uric acid at 12 weeks.
Gout sufferers with major pre-existing heart disease face a higher risk of death if they are treated with the drug febuxostat, a large long-term study has concluded.
The U.S. FDA approved Ironwood Pharmaceuticals Inc.’s Duzallo as a once-daily oral treatment for hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of allopurinol alone.
Switzerland’s Novartis is stocking up cheaper versions of the world’s top-selling arthritis medicines, hoping a broad portfolio gives it an edge on rivals with narrower offerings.
While data help manufacturers fix plant-floor problems and trace quality issues to their source, it also can prevent recalls. Why not proactively use data to attain an end-to-end view of operations so that product quality can be ensured while reducing recalls?
Healthcare conglomerate Johnson & Johnson said the U.S. Justice Department opened an investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that bought two of its drugs.
Regular use of pain relievers over many years may increase the risk of hearing loss, a recent study suggests.